Online inquiry

IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1796MR)

This product GTTS-WQ1796MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1796MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4257MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ471MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ5422MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ7891MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ9809MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ15474MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ5374MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ12658MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-131R10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW